Not Nearly Enough People Are Talking About Chewy Stock

Chewy (NYSE: CHWY) is presented as an attractive investment opportunity, demonstrating robust fundamentals and strategic margin expansion despite a recent Q2 stock pullback driven by rising operating expenses. The company reported 8.6% revenue growth, with Autoship sales up 14.9%, underpinned by a resilient business model with over 80% recurring sales and 85% non-discretionary products. Chewy is actively expanding gross margins through high-margin initiatives like sponsored ads, pet pharmacy services, and private-label brands, which are expected to drive earnings growth beyond sales. Trading at an approximate 25x forward P/E (FY2026 estimates), it offers a valuation discount compared to recession-resistant peers, signaling a compelling long-term entry point.

Analysis

Chewy's (CHWY) recent stock pullback, attributed to rising Q2 operating expenses, appears misaligned with its robust underlying fundamentals and strategic growth vectors. The company's business model demonstrates significant resilience, with over 80% of sales originating from its recurring Autoship program and 85% from non-discretionary products. Despite the market's reaction, Q2 results were strong, featuring an 8.6% year-over-year revenue increase, driven by a 14.9% surge in Autoship customer sales, and a 4.6% rise in net sales per active customer to $591. The core investment thesis rests on margin expansion, which Chewy is pursuing through multiple high-margin channels: sponsored ads with ~70% gross margins, a burgeoning pet pharmacy business with margins up to 10 percentage points above retail, and private-label brands that offer a 700-basis-point margin advantage. With a forward P/E ratio of approximately 25 based on fiscal 2026 estimates, the stock trades at a notable discount to recession-resistant peers like Costco and Walmart, suggesting the market is currently undervaluing its predictable revenue base and clear path to enhanced profitability.

Key Decisions for Investors

• Given the disconnect between the recent stock pullback on operating expense concerns and strong fundamental growth, investors could view the current valuation as an attractive entry point for a long-term position.
• It is crucial to monitor the gross margin trajectory and adoption rates of high-margin initiatives, including pharmacy services, private-label brands, and sponsored ads, as their success is central to the thesis that earnings will outpace sales growth.
• Investors should scrutinize management's ability to control operating expenses in subsequent quarters, as the Q2 cost increase was the primary trigger for the sell-off and sustained cost discipline is necessary to validate the margin expansion thesis.